United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$1.76 (+2.02%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for INCY.OQ


Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The... (more)


Beta: 0.74
Market Cap(Mil.): $16,315.38
Shares Outstanding(Mil.): 187.62
Dividend: --
Yield (%): --


  INCY.OQ Industry Sector
P/E (TTM): 412.84 42.42 37.52
EPS (TTM): 0.21 -- --
ROI: 6.35 -9.34 14.48
ROE: 52.52 -9.70 15.65

Old pharma sees new profit cure in cancer drugs

Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.

Jul 19 2016

BRIEF-FDA grants breakthrough therapy designation for Incyte's Ruxolitinib

* FDA grants breakthrough therapy designation for Incyte's Ruxolitinib (Jakafi) in acute Graft-Versus-Host disease (GVHD) Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780)

Jun 23 2016

BRIEF-Incyte announces first patient treated in ECHO-301 Phase 3 Study

* First patient treated in echo-301 phase 3 study Incyte; expects initial data from echo-301 study to be available in 2018 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 22 2016

BRIEF-Incyte announces phase 3 data of Jakafi study

* Says announced new 28-week data from phase 3 response-2 study of Jakafi

Jun 10 2016

BRIEF-Incyte Corp amends buy-in license deal entered into by Ariad Pharmaceuticals

* On june 1, 2016, amended buy-in license deal entered into by ariad pharmaceuticals, ariad pharmaceuticals (europe) s.a.r.l. & co

Jun 01 2016

BRIEF-Incyte Q1 earnings per share $0.12

* Quarter financial results and updates shareholders on key clinical programs

May 09 2016

BRIEF-Incyte, Lilly provide detailed late-stage data on arthritis drug

* Phase 3 study findings demonstrate treatment with baricitinib results in significant improvements for patients with rheumatoid arthritis who had inadequate response to biologics

Mar 31 2016

BRIEF-Baker Bros Advisors reports 12.6 pct stake in Incyte Corp

* Baker Bros. Advisors LP reports 12.6 percent stake in Incyte Corp as of March 17, 2016 - SEC filing Source text: http://1.usa.gov/1SWMH00 Further company coverage:

Mar 17 2016

Incyte to discontinue testing Jakafi in solid tumor cancers

Incyte Corp said it would stop testing its best-selling blood cancer drug, Jakafi, in solid tumor cancers after the treatment's effectiveness was found to be insufficient in a late-stage study, sending its shares down 16 percent premarket.

Feb 11 2016

UPDATE 2-Incyte to discontinue testing Jakafi in solid tumor cancers

* Shares fall 16 pct to $60 premarket (Adds analyst comment, details, updates shares)

Feb 11 2016


  Price Chg
Pfizer Inc. (PFE.N) $36.85 +0.02
Abbott Laboratories (ABT.N) $43.67 +0.07
Amgen, Inc. (AMGN.OQ) $170.68 +3.01
Biogen Inc (BIIB.OQ) $288.35 +1.31
Roche Holding Ltd. (ROG.S) CHF249.30 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -1.25
Sanofi SA (SASY.PA) €76.70 +0.13

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
Provider : Thomson Reuters Stock Report
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.